GlassScriptPhysician profile
Picha J Moolsintong
NPI 1871702209
$17,135.11
in general payments reported to CMS, 2019-2025
41 companies · $3,305 in 2025
The $3,305 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $1,682 · 2021: $2,196 · 2022: $2,037 · 2023: $2,361 · 2024: $3,328 · 2025: $3,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,925 · Education: $69.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,925.38 |
| Education | $69.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,881.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,949.09 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,812.00 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,704.39 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $1,352.36 | 2019-2025 | |
| Gilead Sciences, INC. | $1,044.35 | 2019-2025 | Livdelzi |
| Celgene Corporation | $511.25 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $511.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $373.40 | 2020-2025 | Avsola, Amjevita, Uplizna |
| Lilly USA, LLC | $367.50 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $343.29 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $318.22 | 2023-2025 | |
| Ucb, INC. | $246.76 | 2019-2022 | |
| Qol Medical, LLC | $230.14 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $219.92 | 2019-2024 | Linzess |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Picha Moolsintong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.